Pharming Group N.V./€PHARM
05:30
09:10
12:45
16:25
20:00
1D1W1MYTD1Y5YMAX
About Pharming Group N.V.
Pharming Group N.V. is a biotechnology company based in Leiden, Netherlands, focused on developing and commercializing innovative protein replacement therapies and precision medicines. The company's primary product, Ruconest, is an approved treatment for acute hereditary angioedema attacks, utilizing a recombinant form of the C1 esterase inhibitor. Established in 1988, Pharming leverages proprietary transgenic technology to produce human therapeutic proteins in the milk of genetically modified animals. With a strategic emphasis on rare diseases, the company aims to expand its pipeline through ongoing research and development activities. Pharming operates primarily in Europe and the United States, with partnerships and collaborations enhancing its global presence.
Ticker
€PHARM
Sector
Primary listing
AEX
Employees
404
Headquarters
Website
PHARM Metrics
BasicAdvanced
€847M
-
-€0.01
0.54
-
Price and volume
Market cap
€847M
Beta
0.54
52-week high
€1.24
52-week low
€0.65
Average daily volume
663K
Financial strength
Current ratio
2.795
Quick ratio
2.039
Long term debt to equity
49.579
Total debt to equity
53.569
Interest coverage (TTM)
1.91%
Profitability
EBITDA (TTM)
22.612
Gross margin (TTM)
89.31%
Net profit margin (TTM)
-2.41%
Operating margin (TTM)
5.78%
Effective tax rate (TTM)
344.42%
Revenue per employee (TTM)
€720,300
Management effectiveness
Return on assets (TTM)
2.85%
Return on equity (TTM)
-3.70%
Valuation
Price to revenue (TTM)
2.785
Price to book
3.54
Price to tangible book (TTM)
8.17
Price to free cash flow (TTM)
31.418
Free cash flow yield (TTM)
3.18%
Free cash flow per share (TTM)
0.038
Growth
Revenue change (TTM)
22.44%
Earnings per share change (TTM)
-34.85%
3-year revenue growth (CAGR)
18.86%
10-year revenue growth (CAGR)
28.33%
3-year earnings per share growth (CAGR)
-25.00%
10-year earnings per share growth (CAGR)
-6.22%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Pharming Group N.V. stock?
Pharming Group N.V. (PHARM) has a market cap of €847M as of August 29, 2025.
What is the P/E ratio for Pharming Group N.V. stock?
The price to earnings (P/E) ratio for Pharming Group N.V. (PHARM) stock is 0 as of August 29, 2025.
Does Pharming Group N.V. stock pay dividends?
No, Pharming Group N.V. (PHARM) stock does not pay dividends to its shareholders as of August 29, 2025.
When is the next Pharming Group N.V. dividend payment date?
Pharming Group N.V. (PHARM) stock does not pay dividends to its shareholders.
What is the beta indicator for Pharming Group N.V.?
Pharming Group N.V. (PHARM) has a beta rating of 0.54. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.